MGHbanner BulfinchBldg
MGH  Neurosurgical Service Home
MGH Neurosurgical Service
Massachusetts General HospitalHarvard Medical School

MGH Shield Hvd Med Sch Shield Partners Logo

Bulletin Volume 5, Issue, Fall 1999

Neuroendocrine & Pituitary Center | Referrals | Neuroendocrine Bulletin Archive
Guestbook
| Neurosurgery Home | Links

Articles in this issue:

Acromegaly: Complications and Therapeutic Update.
Neurocognitive Dysfunction in Patients with Pituitary Ademomas.

ACROMEGALY: COMPLICATIONS AND THERAPEUTIC UPDATE
by Laurence Katznelson, M.D.

Acromegaly is characterized by a number of phenotypic changes including enlargement of the hands and feet, facial changes such as frontal bossing, enlarged mandible and increased dental spacing, arthralgias, fatigue, diaphoresis, sleep apnea, hypertension, diabetes mellitus, and hypertrophic cardiomyopathy. Because it is a rare disorder and development of these clinical features is insidious, patients typically have acromegaly for many years before the diagnosis is made. Approximately 90% of all somatotroph tumors, which cause this disorder, are macroadenomas (>1 cm) at diagnosis. Therefore, these tumors frequently cause local anatomic compression, resulting in visual field deficits, headaches, hypopituitarism and cranial nerve palsies.

The pulsatile release of growth hormone (GH) by normal pituitary somatotroph cells is regulated by growth hormone releasing hormone (GHRH), which stimulates GH secretion, and somatostatin, which decreases secretion. At the liver, GH stimulates secretion of somatomedin C, also known as insulin-like growth factor I (IGF-I). IGF-I mediates many of the peripheral somatic effects of GH and feeds back at the level of the hypothalamus and pituitary resulting in a reduction in GH secretion. Therefore, GH and IGF-I levels are held in tight balance.

The diagnosis of acromegaly is based on three key findings: 1) clinical evidence, 2) demonstration of an elevated IGF-I level, and 3) inability to suppress serum GH to less than 2 ng/ml following an oral glucose challenge (OGTT) using a conventional radioimmunoassay or less than 1 ng/ml using an IRMA or chemiluminescent assay.

Why do we treat? Short term benefits of therapy include improvement of symptoms such as headaches, which are often debilitating. In addition, there are long-term complications of acromegaly that are of concern. There is a 2 to 5 fold increase in the mortality rate in acromegalic patients and this is largely due to cardiovascular and cerebrovascular disease. In a recent long-term follow-up of 162 subjects from the Massachusetts General Hospital, therapy (regardless of modality) of acromegaly with resultant normalization of IGF-1 was associated with a 3.5 fold reduction in the risk of mortality compared to patients with active disease. Therefore, successful management of acromegaly may negate the increased mortality risk.

There are multiple medical complications associated with acromegaly. In part because of hypertension, there is cardiac involvement that includes left ventricular hypertrophy and congestive heart failure. Sleep apnea syndrome (both central and obstructive) is detected in up to 80% of subjects and may result in considerable morbidity. Acromegalics may also develop significant arthropathy that may lead to pain, deformity, and necessitate joint replacement. Left ventricular mass, sleep apnea syndrome, and arthralgias may improve with therapy.

Patients with acromegaly may also be at enhanced risk for cancer, and colon cancer is the most prevalent. This risk is particularly increased in men over 40 years with a positive family history of colon cancer and multiple skin tags. Other malignancies, including breast cancer, have been described. It is unknown whether successful treatment of acromegaly will reduce the risk of neoplasia.

The primary mode of therapy for acromegaly is surgery to reverse the mass effect and attempt biochemical cure. Surgical cure is dependent on surgical skill and experience as well as the size of the tumor. Cure, defined as normalization of IGF-1 levels and normalization of the GH response to an OGTT, is demonstrated in up to 88% of patients with microadenomas (<1cm). In contrast, up to 50-65% of acromegalic patients with macroadenomas are cured following transsphenoidal surgery. Residual disease following transsphenoidal surgery is therefore common, indicating the need for adjuvant therapy. Radiation therapy is a potential adjuvant therapy for patients with residual disease, however, there is a delayed effect in that 1/2 to 2/3 of subjects attain GH levels < 5 ng/ml by 10 years and normalization of IGF-1 is more difficult to achieve. Hypopituitarism is a significant complication of radiation therapy. Therefore, in most patients, medical management may be necessary in surgically non-cured patients in lieu of or in combination with radiation.

Medical management is a highly useful adjuvant therapy for patients with residual disease or, in selected subjects, as potential de novo medical therapy. Dopamine agonists, including bromocriptine (Parlodel) may normalize GH and IGF-1 levels, but in only 8% of patients. A new longer acting dopamine agonist, cabergoline (Dostinex) is often better tolerated than bromocriptine. Cabergoline may have improved efficacy compared to bromocriptine and should be considered as an oral, therapeutic option in patients with mild disease.

The most efficacious form of medical therapy available includes somatostatin analogs, such as octreotide. Many studies have demonstrated the efficacy of octreotide in the management of acromegaly. The initial octreotide dose is usually 50 mcg b.i.d., and doses may be increased to 250 or 500 mcg t.i.d. depending on the response of circulating GH and IGF-1 levels. However, most studies show 300-900 mcg per day is an effective dose. Octreotide administration results in a decrease in GH and IGF-1 levels in a majority of patients with normalization of IGF-1 levels in up to 60% of patients, indicating biochemical remission. Most patients note a marked improvement in their symptoms of acromegaly very soon after starting octreotide therapy, including headaches, joint pains and diaphoresis. The most significant adverse effect of somatostatin analogs is the development of gallstones, so ultrasounds should be obtained initially. However, the development of symptomatic gallstones is very rare and the need for serial ultrasounds is controversial. Other side effects include gastrointestinal disturbances with nausea, abdominal pain and diarrhea which often occur after initiation of therapy but usually resolve within 1 to 2 weeks.

A new approach to management of acromegaly with somatostatin analogs has been the development of longer acting, depot formulations of somatostatin analogs. These analogs are administered intramuscularly at 2 to 4 week intervals. Sandostatin LAR (long acting release formulation of Sandostatin) was recently approved for use in the United States. Sandostatin LAR is available in 3 doses: 10 mg, 20 mg, and 30 mg and is administered once a month. The efficacy and safety of Sandostatin LAR are similar to that of Sandostatin, but the benefits of this depot preparation on quality of life and compliance have been clear. Another depot formulation of the somatostatin analog lanreotide is available in Europe and is currently under investigation in the United States.

An exciting and novel therapy for acromegaly currently under development is a growth hormone antagonist (GHA). This GHA competes with natural GH for binding to its receptor and, additionally, prevents receptor activation. This leads to lowering of IGF-1 levels. In a recent study presented as an abstract at the Endocrine Society, administration of a GHA in a randomized, double blind placebo controlled trial to 46 acromegalics resulted in normalization of IGF-1 levels in 92% of subjects. This included patients resistant to somatostatin analogs. A GHA may have a critical role in the management of acromegalic patients, particularly in those resistant to or intolerant of conventional medical therapy.

References

1. Ho KY, Weissberger AJ, Marbach P, Lazarus MB. Therapeutic efficacy of the somatostatin analog SMS 201-995 (Octreotide) in acromegaly. Ann Int. Med. 1990; 112:173-81.

2. Serri O, Somma M, Comtois R, Rasio E, Beauregard H, Jilwan N, Hardy J. Acromegaly: biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy. J Clin Endocrinol Metab. 1985; 61: 1185-9.

3. Bates A.S., Van’t Hoff W., Jones J.M. Does treatment of acromegaly affect life expectancy? Metab. 1995;44: 1-5.

4. Swearingen B, Barker FG (II), Katznelson L, Biller BMK, Grinspoon S, Klibanski, Moayeri N, Peter McL. Black, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998; 83: 3419-26.

5. Lancranjan I, Bruns C, Grass P, et al. Sandostatin̉ LAR̉ : A promising therapeutic tool in the management of acromegalic patients. Metabolism. 1996; 45, 67-71.

6. Barkan A, Dimeraki E, Besser GM, et al. Treatment of acromegaly with B2036-PEG, a GH receptor antagonist. Abstract. 1999 Endocrine Society Meeting.

NEUROCOGNITIVE DYSFUNCTION IN PATIENTS WITH PITUITARY ADENOMAS.
by Wesley P. Fairfield, M.D.

"It is quite probable that the psychopathology of everyday life hinges largely upon the effects of a ductless gland discharge upon the nervous system" Harvey Cushing, 1913.

Introduction and Overall Concepts

Patients with pituitary adenomas have a higher prevalence of cognitive dysfunction than found in the general population. The current literature has evaluated this association with case control studies and are subject to the many biases inherent to retrospective analyses. Although pituitary adenomas account for 10-15% of intracranial tumors, their relatively low prevalence makes systematic prospective evaluation difficult. In addition, clinical endpoints to evaluate cognitive functioning are often poorly standardized. It is entirely plausible that pituitary adenomas are linked to cognitive changes. The pituitary gland is situated in a region of the diencephalon known to be important for memory processing. Patients who have been diagnosed and treated for a pituitary adenoma may be exposed to several factors which contribute to changes in cognition including mass effect, hormone hypersecretion, hormone hyposecretion, radiation damage, surgical damage and psychiatric issues related to concomitant medical illness. Given a 9% prevalence of mood disorders in the general outpatient population, most of the neurocognitive changes observed in patients with small non-functioning pituitary adenomas without surgical or radiation therapy are likely to be coincidental. The prevalence of cognitive dysfunction in patients with pituitary tumors and the relative contribution of known variables will be discussed.

Mass effect

Pituitary tumors can present with raised intracranial pressure, pituitary dysfunction or visual field compromise. Other tumors commonly located in the region of the sella turcica include craniopharyngiomas and suprasellar meningiomas and can present with similar symptoms. Each of these tumors may produce alteration in mental status that precedes the aforementioned features. In one retrospective review of 49 patients with cranio-pharyngiomas, the initial presenting feature was mental status abnormalities in 19% of cases. Attribution of cognitive changes directly to mass effect is confounded by the association of large sellar tumors with hypopituitarism as well as surgical and radiation therapies employed to treat these tumors.

Hormone Hypersecretion

Some forms of pituitary tumors may result in psychiatric disturbance attributable to hormone hypersecretion by the pituitary adenoma in the absence of mass effect, hypopituitarism, surgical therapy or radiation therapy. Harvey Cushing in his original description reported emotional disturbance as a prominent feature of the syndrome bearing his name. Subsequently many series have documented a high rate of neuropsychological deficits with endogenous hypercortisolemia including cognitive changes, affective disorders, disordered vegetative functions and acute psychoses. In a series of 209 patients with Cushing’s, nearly 60% had significant psychiatric illness and while the severity did not correlate with degree of hypercortisolemia the depression was alleviated with adrenalectomy. In a study by Dorn et. al., 33 patients with active Cushing’s syndrome (29 with pituitary adenomas) were evaluated before as well as 3, 6 and 12 months after correction of their hypercortisolism. At baseline, 67% of patients had significant psychopathology which persisted in 24% of patients at least 12 months after cure despite recovery of the hypothalamic-pituitary-adrenal axis by conventional criteria. The authors speculate that long-term exposure to high levels of cortisol may cause persistent psychiatric abnormalities through dysregulation of hypothalamic CRH production, an area of active investigation. Psychiatric symptoms attributable to hypercortisolemia have also been reported in association with adrenal ACTH-independent hypercortisolemia as well as ectopic ACTH-dependent hypercortisolemia arguing against any psychiatric effect of the pituitary adenoma itself, independent of hypercortisolemia in Cushing’s disease. In addition, the neurocognitive and behavioral effects of exogenous glucocorticoids are well described. However, the depression observed with Cushing’s syndrome is often contrasted with the mood elevation observed with exogenously administered therapeutic steroids. These differences are presumed to be related to either the chronicity of hypercortisolemia or differing levels of biologically active steroids centrally and peripherally in the two different scenarios.

In several case reports, hyperprolactinemia has been reported in association with psychiatric disease independent of the use of psychotropic medications. It is not clear that an association exists and in many such reports, it is difficult to determine which effects may be due to estrogen deficiency or other gonadal steroid changes versus the effects of hyperprolactinemia alone.

The psychiatric accompaniments of acromegaly have not been studied systematically although mood lability, apathy and lack of initiative have been reported in association with this disorder. Determination of an independent psychiatric effect of having a somatotroph adenoma from the physical disfigurement and symptoms associated with acromegaly is likely to be difficult.

Hormone hyposecretion

Hypopituitarism may result from impairment of normal pituitary function by a pituitary adenoma. Neuropsychiatric abnormalities have commonly been reported in association with hypopituitarism including depression, apathy, and memory impairment. In addition, cognitive changes are a well described feature of hypogonadism, hypothyroidism, and adrenal insufficiency. Some studies have reported neuropsychiatric abnormalities in patients with growth hormone deficiency which improve with growth hormone therapy. However in a study conducted at our center, Baum et. al. investigated the effects of growth hormone on cognitive function in 40 men treated for hypopituitarism (32 had pituitary adenomas), all with untreated growth hormone deficiency. Patients were randomized to receive either physiologic doses of growth hormone or placebo in a double-blinded fashion. Patients with growth hormone deficiency tested normally with respect to cognitive functioning and IQ though scored relatively lower on tests of memory and learning when compared with a standardized population. At baseline and after 18 months of therapy, there were no differences observed in cognitive function testing, psychometric testing and sense of well being assessments. Neuropsychiatric abnormalities are subtle (if present) in patients with adult-onset growth hormone deficiency and neuropsychiatric function does not appear to improve with growth hormone replacement therapy. Patients with cognitive defects attributable to hypogonadism, adrenal insufficiency and hypothyroidism typically respond to hormone replacement therapy as indicated. However, patients with long-standing hypopituitarism have been described with persistent apathy and loss of drive despite the institution of replacement therapy.

Surgical therapy

The type of surgery used to remove pituitary tumors has evolved with advances in technology. The transfrontal route was the most widely used approach until the development of the intraoperative microscope resulting in faster and easier access to the pituitary via the transsphenoidal route when performed by an experienced neurosurgeon. Transsphenoidal surgery is considered less traumatic to the patient. Transfrontal surgery can still be used for very large tumors inaccessible via a transsphenoidal route and it is speculated that retraction of the frontal lobe may damage small perforating arteries of the internal carotid artery resulting in focal infarction and vasospasm. Any association observed in retrospective studies linking surgical therapy and neurocognitive changes will be confounded by selection bias as many larger tumors are more likely to be treated surgically, often receive adjunctive radiation therapy, and are associated with hypopituitarism.

Radiation therapy

Radiation was first used for the treatment of pituitary tumors in 1909 and remains one of the primary modalities of therapy for patients particularly with unresectable pituitary macroadenomas. The existence of long-term neuropsychological changes directly attributable to previous radiation therapy is debated in the literature. The incidence of side effects resulting from radiation therapy in the treatment of a pituitary adenoma is generally considered to be very low. However, hypopituitarism as a late sequelae in these patients is increasingly being recognized. Radiation necrosis is a well-documented complication of radiation therapy often resulting in severe impairment in cognition but is considered a rare side effect in patients receiving radiation therapy for pituitary adenomas.

Neurocognitive and Neuropsychologic Tests

Grattan-Smith et al described the spectrum of neuropsychological abnormalities in a series of patients with pituitary tumors. Although their primary interest was in patients treated with radiotherapy (38 patients), they extended the study to patients treated medically or surgically (27 patients) as well as a series of 21 inpatients with chronic disease used as controls. Specific tests evaluated patients by using eight neuropsychological tests in three domains: executive functioning, verbal memory, and visual memory. Both groups of pituitary tumor patients performed below clinically accepted norms on seven of eight tests, and performed well below the level of controls on tests of executive functioning, verbal and visual memory. Performance on the tests did not differ among pituitary patients treated with radiation versus other therapy. Although this study provides helpful descriptive data on neuropsychological abnormalities in these patients, the authors did not report the overall prevalence of specific deficits, and the study had several major limitations. The authors did not assess patients for depression, nor did they adjust for time interval since diagnosis and treatment. They were not able to adjust for other potentially confounding factors associated with poorer function including type of tumor, medication or recent treatment effects, and intercurrent illness. A final critical point is that since most patients had been treated before the study began, it was impossible to distinguish effects of the tumor from treatment effects.

A recent study by Peace et al examined 69 patients with pituitary tumors (23 each having undergone either transfrontal surgery, transsphenoidal surgery, or medical treatment), and 23 healthy controls . Some of the patients in both surgical groups received radiotherapy as well, and all surgeries were performed at least two years prior to the study. Attention, memory, and executive function were assessed using seven specific tests, in addition to a test for overall intelligence. The authors reported deficits in executive function and memory among patients with tumors, although patients treated medically had milder memory deficits. Patients treated with transfrontal surgery had the greatest degree of cognitive impairment, with 43.5% having three or more test scores below the 10th percentile. Among transsphenoidal patients, 30.4% scored below the 10th percentile on three or more tests, compared with 21.7% of medically treated patients, and 5% of controls. The authors do not report when surgery was performed and may overestimate the impact of surgical therapy given recent developments of new neurosurgical techniques resulting in less damage and less frequent use of anti-seizure medications which can also interfere with cognition. Radiotherapy treatment did not appear to affect test scores. Since treatment decisions are necessarily nonrandom, differences between treatment groups are subject to substantial selection bias and are not directly comparable. The strength of this study is that it highlights the high prevalence of cognitive abnormalities among patients with pituitary tumors, including those treated non-surgically.

In the largest study, Guinan described neuropsychological testing among 90 patients treated for pituitary adenoma of any etiology. Treatment groups included transfrontal surgery, transsphenoidal surgery with or without radiotherapy, radiotherapy only, and bromocriptine only. The investigators assessed general intellectual function, memory, executive function, language comprehension, and speed of mental processing. The authors of this study also found substantial memory deficits in all treatment groups compared with healthy controls. Anterograde memory was most substantially affected. Treatment group did not correlate with degree of impairment in general, although bromocriptine-treated patients had less impairment on one test of anterograde memory. Additional analyses showed no association between cognitive function and tumor type or time elapsed since treatment. This study was able to control for psychiatric disease and examine effects of interval since treatment. As with the reports from Grattan-Smith and Peace, the retrospective design limits evaluation of treatment effects, since selection bias is expected to strongly influence treatment choice and outcome. Nonetheless, these reports suggest that neuropsychological deficits, particularly memory impairment, are common among patients with pituitary tumors and persist long after treatment completion.

Summary

Patients with pituitary adenomas appear to be at risk for the development of neuropsychiatric abnormalities. Patients with Cushing’s disease appear to be particularly at risk for the development of psychiatric abnormalities. The available literature has not established an independent association between having a pituitary adenoma and cognitive changes when accounting for mass effect, hormone hypersecretion, hypopituitarism, surgical therapy and radiation therapy. Patients who report impaired memory or other neuropsychiatric symptoms should be evaluated with formal neuropsychiatric testing and referred appropriately based upon the results.

References

  1. Cushing H. Psychic disturbances associated with disorders of the ductless glands. Am J Insanity 1913; 69:965-990.
  2. Crane TB, Yee RD, Hepler RS, Hallinan JM. Clinical manifestations and radiologic findings in craniopharyngiomas in adults. Am J Ophthalmol 1982; 94:220-8.
  3. Cushing H. Basophilic adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 1932; 50:137.
  4. Dorn LD, Burgess ES, Dubbert B, et al. Psychopathology in patients with endogenous Cushing's syndrome: 'atypical' or melancholic features. Clin Endocrinol (Oxf) 1995; 43:433-42.
  5. Kelly WF. Psychiatric aspects of Cushing's syndrome. QJM 1996; 89:543-51.
  6. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997; 82:912-9.
  7. Baum HB, Katznelson L, Sherman JC, et al. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998; 83:3184-9.
  8. Grattan-Smith PJ, Morris JG, Langlands AO. Delayed radiation necrosis of the central nervous system in patients irradiated for pituitary tumours. J Neurol Neurosurg Psychiatry 1992; 55:949-55.
  9. Peace KA, Orme SM, Padayatty SJ, Godfrey HP, Belchetz PE. Cognitive dysfunction in patients with pituitary tumour who have been treated with transfrontal or transsphenoidal surgery or medication. Clin Endocrinol (Oxf) 1998; 49:391-6.
  10. Guinan EM, Lowy C, Stanhope N, Lewis PD, Kopelman MD. Cognitive effects of pituitary tumours and their treatments: two case studies and an investigation of 90 patients. J Neurol Neurosurg Psychiatry 1998; 65:870-6.

[Neuroendocrine Clinical Home]Neuroendocrine & Pituitary Center | Referrals
Neuroendocrine Bulletin Archive | Guestbook | Neurosurgery Home | Links

[Divider]
[Divider]

MASSGENERAL
LEGAL ISSUES

[Divider]
Last Updated February 10, 2005
[Divider]
Disclaimer About Medical Information: The information and reference materials contained herein is intended solely for the information of the reader. It should not be used for treatment purposes, but rather for discussion with the patient's own physician. All visitors to this and associated sites from the Neurosurgical Service at MGH agree to read and abide by the the complete terms of legal agreement found at the Neurosurgery "disclaimer & legal agreement." See also: the MGH Disclaimer, the MGH Privacy Policy, and the MGH Interactive Program Disclaimer - Visitors must read the disclaimer - legal agreement. All Rights Reserved. Copyright © 2007 MGH Neuroendocrin Clinical Center - e-mail C.Owen
[Divider]
electronswebs
MGH  Neurosurgical Service Home

Neuroendocrine
Clinical Center

Physicians' Pituitary Information Service - Physicians with questions may contact Dr Biller or DR Klibanski at 617.726.3965 or 1.888.429.6863 or via e-mail pituitary.info@partners.org
Voice:  617.726.7948
Fax:  617.726.1241

Clinical Research Studies
Clinical Research Studies in Pituitary Disorders
Clinical Research Studies in Anorexia Nervosa